Ocular Therapeutix announced that Executive Chairman, Pravin Dugel, MD, is assuming the roles of President and Chief Executive Officer, and that Antony Mattessich is stepping down as President and CEO, effective immediately. In addition to his new responsibilities, Dr. Dugel will continue to serve as a director and as Executive Chairman of Ocular. Pravin U. Dugel, MD has held previous leadership roles including President of IVERIC Bio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
- Ocular Therapeutix reports inducement grants under Nasdaq listing rule
- Ocular Therapeutix announces Phase 2 PAXTRAVA glaucoma data
- Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
- Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
